Naveen S Vasudev1, Janet E Brown. 1. Cancer Research UK Clinical Centre at Leeds, University of Leeds, St James's Hospital, Leeds, UK.
Abstract
PURPOSE OF REVIEW: To highlight recent advances in the medical management of metastatic bone disease. RECENT FINDINGS: Progress has been made in quality of life assessment and pain measurement; in novel ways to use bisphosphonates, especially in the adjuvant setting for prevention of bone metastases and in combination with other pharmaceutical agents, where synergistic enhancement holds high potential; in targeted therapies using novel agents, especially with denosumab which is approaching registration; in the use of bone biomarkers to direct therapy and as surrogate endpoints; in development of radiopharmaceuticals for improved treatment of disseminated bone pain. SUMMARY: Metastatic bone disease continues to present management challenges, but these challenges are being met with an increased armamentarium of available interventions.
PURPOSE OF REVIEW: To highlight recent advances in the medical management of metastatic bone disease. RECENT FINDINGS: Progress has been made in quality of life assessment and pain measurement; in novel ways to use bisphosphonates, especially in the adjuvant setting for prevention of bone metastases and in combination with other pharmaceutical agents, where synergistic enhancement holds high potential; in targeted therapies using novel agents, especially with denosumab which is approaching registration; in the use of bone biomarkers to direct therapy and as surrogate endpoints; in development of radiopharmaceuticals for improved treatment of disseminated bone pain. SUMMARY: Metastatic bone disease continues to present management challenges, but these challenges are being met with an increased armamentarium of available interventions.
Authors: Ajit S Shinto; Madhava B Mallia; Mythili Kameswaran; K K Kamaleshwaran; Jephy Joseph; E R Radhakrishnan; Indira V Upadhyay; R Subramaniam; Madhu Sairam; Sharmila Banerjee; Ashutosh Dash Journal: World J Nucl Med Date: 2018 Oct-Dec
Authors: Shafaq Sikandar; Ryan Patel; Sital Patel; Sanam Sikander; David L H Bennett; Anthony H Dickenson Journal: Eur J Pharmacol Date: 2013-03-13 Impact factor: 4.432